Display options
Cite
Vasekar M, Liu X, Zheng H, et al. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014;5(2):39-47doi: 10.5306/wjco.v5.i2.39.
Vasekar, M., Liu, X., Zheng, H., & Belani, C. P. (2014). Targeted immunotherapy for non-small cell lung cancer. World journal of clinical oncology, 5(2), 39-47. https://doi.org/10.5306/wjco.v5.i2.39
Vasekar, Monali, et al. "Targeted immunotherapy for non-small cell lung cancer." World journal of clinical oncology vol. 5,2 (2014): 39-47. doi: https://doi.org/10.5306/wjco.v5.i2.39
Vasekar M, Liu X, Zheng H, Belani CP. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10;5(2):39-47. doi: 10.5306/wjco.v5.i2.39. PMID: 24829850; PMCID: PMC4014795.
Copy Download .nbib Format: NLM
Share it on

World J Clin Oncol. 2014 May 10;5(2):39-47. doi: 10.5306/wjco.v5.i2.39.

Targeted immunotherapy for non-small cell lung cancer.

World journal of clinical oncology

Monali Vasekar, Xin Liu, Hong Zheng, Chandra P Belani

Affiliations

  1. Monali Vasekar, Xin Liu, Hong Zheng, Chandra P Belani, Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, PA 17033, United States.

PMID: 24829850 PMCID: PMC4014795 DOI: 10.5306/wjco.v5.i2.39

Abstract

Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.

Keywords: Cytotoxic T-Lymphocyte Antigen-4; Immunotherapy; Non-small cell lung cancer; Programmed death ligands 1; Programmed death-1

References

  1. N Engl J Med. 2009 Sep 3;361(10):947-57 - PubMed
  2. Science. 2011 Mar 25;331(6024):1565-70 - PubMed
  3. Cancer. 2008 Sep 15;113(6):1387-95 - PubMed
  4. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  5. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  6. Cancer. 1999 Nov 1;86(9):1712-9 - PubMed
  7. J Thorac Oncol. 2010 May;5(5):585-90 - PubMed
  8. Immunol Rev. 2009 May;229(1):67-87 - PubMed
  9. Cancer Gene Ther. 2009 Aug;16(8):620-4 - PubMed
  10. Nat Med. 2002 Aug;8(8):793-800 - PubMed
  11. Semin Oncol. 2010 Oct;37(5):430-9 - PubMed
  12. J Clin Oncol. 2010 Jul 1;28(19):3167-75 - PubMed
  13. Nat Rev Cancer. 2005 May;5(5):341-54 - PubMed
  14. J Clin Oncol. 2012 Jun 10;30(17):2046-54 - PubMed
  15. Clin Cancer Res. 2003 Mar;9(3):947-54 - PubMed
  16. J Clin Oncol. 2006 Oct 10;24(29):4721-30 - PubMed
  17. Immunogenetics. 1994;40(5):360-9 - PubMed
  18. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  19. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):309-16 - PubMed
  20. J Clin Oncol. 2008 Nov 10;26(32):5275-83 - PubMed
  21. N Engl J Med. 2002 Jan 10;346(2):92-8 - PubMed
  22. Lung. 2011 Dec;189(6):453-60 - PubMed
  23. J Immunol. 2013 Aug 15;191(4):2009-17 - PubMed
  24. Eur J Cancer. 2011 Sep;47 Suppl 3:S364-5 - PubMed
  25. J Clin Oncol. 2013 Jul 1;31(19):2396-403 - PubMed
  26. Lancet Oncol. 2011 Aug;12(8):735-42 - PubMed
  27. Semin Oncol. 2010 Oct;37(5):499-507 - PubMed
  28. J Clin Oncol. 2005 Sep 20;23(27):6674-81 - PubMed
  29. Clin Cancer Res. 2005 Nov 15;11(22):8055-62 - PubMed
  30. Clin Cancer Res. 2008 Feb 1;14(3):840-6 - PubMed
  31. Oncology. 2006;70(1):54-62 - PubMed
  32. Clin Lung Cancer. 2001 Aug;3(1):49-57; discussion 58 - PubMed
  33. J Cancer Res Clin Oncol. 2011 Sep;137(9):1337-42 - PubMed
  34. Clin Cancer Res. 2009 Dec 1;15(23):7412-20 - PubMed
  35. Cancer Biol Ther. 2006 Feb;5(2):145-9 - PubMed
  36. Nature. 2011 Dec 21;480(7378):480-9 - PubMed
  37. Immunity. 1995 Feb;2(2):167-75 - PubMed
  38. J Exp Med. 2003 Dec 15;198(12):1875-86 - PubMed
  39. N Engl J Med. 2010 Jul 29;363(5):411-22 - PubMed
  40. Lancet Oncol. 2014 Jan;15(1):59-68 - PubMed
  41. Br J Cancer. 2006 Jan 30;94(2):275-80 - PubMed
  42. Ann Oncol. 2000 Jul;11(7):799-805 - PubMed
  43. Cancer Res. 2000 Nov 15;60(22):6272-5 - PubMed
  44. Lancet Oncol. 2012 Mar;13(3):239-46 - PubMed

Publication Types